Sandoz’s Nick Haggar named new EGA president
Holzkirchen, Germany, October 02, 2013 – The European Generic medicines Association (EGA) has named Sandoz’s Nick Haggar as the new incoming president of the European generic medicines industry body.
Nick will take over the role on October 8, 2013 alongside his responsibilities at Sandoz as Head of Western Europe, Middle East and Africa.
“I am delighted to take up the presidency of the EGA and to support the association in its efforts to promote generic and biosimilar medicines in Europe,” said Nick Haggar. “The generic and biosimilar medicines industry makes an enormous contribution to public health by providing high-quality, affordable medication to patients across Europe. The EGA has a vital role in promoting and communicating the value, safety and efficacy of generic and biosimilar medicines.”
“We are pleased that Nick will represent the generic and biosimilar medicines industry at a European level through the EGA. This is an honor for Nick and for Sandoz,” said Jeff George, Global Head of Sandoz. “We look forward to continuing to support the EGA and the industry in how best to make generic and biosimilar medicines available to more patients throughout Europe.”
The EGA is the official representative body of the European generic and biosimilar pharmaceutical industry. Founded in 1993, the EGA represent generic pharmaceutical companies and their subsidiaries throughout Europe.
On October 8, 2013, Nick will speak about the value of generic and biosimilar medicines at the Industrial Policy Conference in Brussels, hosted by the EGA.
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the rapidly growing generics industry. Sandoz employs over 26,000 employees in more than 140 countries, offering broad range of over 1,000 high-quality, affordable products that are no longer protected by patents. With USD 8.7 billion in sales in 2012, Sandoz holds the #1 position globally in biosimilars as well as generic injectables, ophthalmics, dermatology and anti-biotics as well as strong positions in the treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments, and hormone therapies. Sandoz develops, produces, and markets these medicines along with pharmaceutical and biotechnological active substances. In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003 , Sandoz has benefitted from strong growth of its acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/sandoz.